METiS TechBio announced a strategic collaboration with Eli Lilly and Company focused on researching and discovering novel lipid nanoparticle (LNP)-based delivery solutions designed to enable ...
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, ...
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim ...
FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data ...
Hansoh Pharmaceutical Group Co., Ltd. announced it has entered into a strategic collaboration and license agreement with Roche covering a broad portfolio of antibody-drug conjugat ...
Pharmaceutical Executive spoke with John Stanford, executive director at Incubate, about the current status of MFN and how ...
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval. The European Medicines Agency’s Committee for Medicinal ...
AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results